

Erik P Sulman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9543075/publications.pdf>

Version: 2024-02-01

197
papers

22,967
citations

22153

59
h-index

8866

145
g-index

208
all docs

208
docs citations

208
times ranked

28435
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	27.0	2,582
2	A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 699-708.	27.0	2,279
3	Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. <i>Cancer Cell</i> , 2010, 17, 510-522.	16.8	2,078
4	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. <i>Cancer Cell</i> , 2017, 32, 42-56.e6.	16.8	1,282
5	m 6 A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. <i>Cancer Cell</i> , 2017, 31, 591-606.e6.	16.8	1,131
6	The transcriptional network for mesenchymal transformation of brain tumours. <i>Nature</i> , 2010, 463, 318-325.	27.8	1,114
7	Mesenchymal Differentiation Mediated by NF- κ B Promotes Radiation Resistance in Glioblastoma. <i>Cancer Cell</i> , 2013, 24, 331-346.	16.8	856
8	Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1040-1048.	10.7	537
9	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. <i>Neuro-Oncology</i> , 2014, 16, 81-91.	1.2	370
10	Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 895-902.	1.6	366
11	Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. <i>JCI Insight</i> , 2016, 1, .	5.0	356
12	A multigene predictor of outcome in glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 49-57.	1.2	334
13	The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. <i>Genes and Development</i> , 2011, 25, 2594-2609.	5.9	326
14	MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 116-121.	1.2	316
15	TERT Promoter Mutations and Risk of Recurrence in Meningioma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv377.	6.3	283
16	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2386-2394.	1.6	276
17	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. <i>Acta Neuropathologica</i> , 2015, 129, 585-596.	7.7	272
18	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 492-516.	1.6	261

#	ARTICLE	IF	CITATIONS
19	Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2288-2294.	1.6	260
20	Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. <i>Oncolmmunology</i> , 2018, 7, e1412909.	4.6	247
21	IMRT Reirradiation of Head and Neck Cancer Disease Control and Morbidity Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 399-409.	0.8	218
22	Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. <i>Cell</i> , 2016, 167, 1281-1295.e18.	28.9	207
23	MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. <i>Cancer Cell</i> , 2017, 32, 840-855.e8.	16.8	188
24	Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2013, 19, 4392-4403.	7.0	164
25	Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. <i>Stem Cells</i> , 2015, 33, 2400-2415.	3.2	163
26	Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation. <i>Cell Reports</i> , 2019, 26, 1893-1905.e7.	6.4	161
27	EZH2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK/FOXM1-Dependent Manner. <i>Stem Cell Reports</i> , 2015, 4, 226-238.	4.8	159
28	Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. <i>Acta Neuropathologica</i> , 2017, 133, 431-444.	7.7	155
29	Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF- κ B-dependent Manner. <i>Cancer Cell</i> , 2016, 29, 201-213.	16.8	147
30	Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 1888-1899.	1.6	146
31	G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. <i>Nature Communications</i> , 2019, 10, 943.	12.8	132
32	Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 1094-1104.	7.0	124
33	Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. <i>BMC Medical Genomics</i> , 2011, 4, 34.	1.5	119
34	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018, 20, 873-884.	1.2	119
35	A High Notch Pathway Activation Predicts Response to γ Secretase Inhibitors in Proneural Subtype of Glioma Tumor-Initiating Cells. <i>Stem Cells</i> , 2014, 32, 301-312.	3.2	117
36	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Neuro-Oncology</i> , 2017, 19, now208.	1.2	109

#	ARTICLE	IF	CITATIONS
37	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 361-369.	1.6	109
38	Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 2239-2245.	1.6	104
39	Cancer stem cells: markers or biomarkers?. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 459-470.	5.9	102
40	Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv369.	6.3	102
41	Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. <i>Cancer Cell</i> , 2019, 35, 504-518.e7.	16.8	102
42	Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/β-Catenin Signaling. <i>Stem Cells</i> , 2012, 30, 2366-2377.	3.2	100
43	MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy. <i>Autophagy</i> , 2019, 15, 1100-1111.	9.1	100
44	Predictors of Survival in Contemporary Practice After Initial Radiosurgery for Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 656-661.	0.8	98
45	Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 2048-2049.	27.0	98
46	Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma. <i>Brain Pathology</i> , 2015, 25, 266-275.	4.1	97
47	Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. <i>Nature Genetics</i> , 2021, 53, 1088-1096.	21.4	94
48	Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. <i>Oncogene</i> , 2015, 34, 1619-1628.	5.9	82
49	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now257.	1.2	80
50	Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. <i>Neuro-Oncology</i> , 2021, 23, 284-294.	1.2	78
51	A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. <i>Genes and Development</i> , 2013, 27, 1462-1472.	5.9	74
52	A Coclinal Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. <i>Clinical Cancer Research</i> , 2018, 24, 6288-6299.	7.0	74
53	Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. <i>Genome Biology</i> , 2020, 21, 216.	8.8	73
54	A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. <i>Nature Communications</i> , 2016, 7, 12885.	12.8	72

#	ARTICLE	IF	CITATIONS
55	Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. <i>Journal of Clinical Investigation</i> , 2013, 123, 405-417.	8.2	70
56	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	7.0	67
57	Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. <i>Nature Communications</i> , 2018, 9, 1057.	12.8	66
58	Physical Mapping and Genomic Structure of the Human TNFR2 Gene. <i>Genomics</i> , 1996, 35, 94-100.	2.9	65
59	Dosimetric Predictors of Duodenal Toxicity After Intensity Modulated Radiation Therapy for Treatment of the Para-aortic Nodes in Gynecologic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 357-362.	0.8	62
60	Molecular Markers in Low-Grade Glioma—Toward Tumor Reclassification. <i>Seminars in Radiation Oncology</i> , 2015, 25, 155-163.	2.2	62
61	MerTK as a therapeutic target in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 92-102.	1.2	62
62	A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. <i>Scientific Reports</i> , 2019, 9, 1322.	3.3	62
63	ECK, a Human EPH-Related Gene, Maps to 1p36.1, a Common Region of Alteration in Human Cancers. <i>Genomics</i> , 1997, 40, 371-374.	2.9	60
64	Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. <i>Radiation Oncology</i> , 2009, 4, 5.	2.7	59
65	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. <i>Radiotherapy and Oncology</i> , 2017, 125, 80-88.	0.6	58
66	A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities. <i>Nature Communications</i> , 2020, 11, 2935.	12.8	57
67	Bayesian ensemble methods for survival prediction in gene expression data. <i>Bioinformatics</i> , 2011, 27, 359-367.	4.1	56
68	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. <i>Cell Reports</i> , 2017, 21, 2183-2197.	6.4	56
69	PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. <i>Molecular Cell</i> , 2021, 81, 1276-1291.e9.	9.7	54
70	Mir-21—Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. <i>Journal of Neuroscience</i> , 2015, 35, 15097-15112.	3.6	53
71	Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. <i>Clinical Cancer Research</i> , 2017, 23, 6215-6226.	7.0	53
72	Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. <i>Neuro-Oncology</i> , 2018, 20, 192-202.	1.2	52

#	ARTICLE	IF	CITATIONS
73	Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase- α -mutant Glioma. <i>Clinical Cancer Research</i> , 2019, 25, 1261-1271.	7.0	50
74	A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1337-1347.	1.2	50
75	Novel Therapies for Glioblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 19.	4.2	50
76	Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34. <i>Oncogene</i> , 2004, 23, 1014-1020.	5.9	47
77	Molecular profiling of long-term IDH-wildtype glioblastoma survivors. <i>Neuro-Oncology</i> , 2019, 21, 1458-1469.	1.2	47
78	Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. <i>Cancer</i> , 2019, 125, 424-433.	4.1	46
79	Loss of H3K27me3 in meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1282-1291.	1.2	45
80	A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated <i>MGMT</i> glioblastoma: the VERTU study. <i>Neuro-Oncology</i> , 2021, 23, 1736-1749.	1.2	44
81	Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 1469-1480.	1.2	42
82	PAF promotes stemness and radioresistance of glioma stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9086-E9095.	7.1	40
83	Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. <i>Neuro-Oncology</i> , 2017, 19, now239.	1.2	39
84	CDK4/6 inhibition is more active against the glioblastoma proneural subtype. <i>Oncotarget</i> , 2017, 8, 55319-55331.	1.8	39
85	Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. <i>Clinical Cancer Research</i> , 2020, 26, 4983-4994.	7.0	38
86	An Integrated Transcript Map of Human Chromosome 1p35-p36. <i>Genomics</i> , 1997, 42, 126-136.	2.9	36
87	Multomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. <i>Genome Biology</i> , 2020, 21, 271.	8.8	36
88	Ionizing radiation augments glioma tropism of mesenchymal stem cells. <i>Journal of Neurosurgery</i> , 2018, 128, 287-295.	1.6	34
89	TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1. <i>Science Advances</i> , 2016, 2, e1501290.	10.3	33
90	The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 292-300.	6.3	32

#	ARTICLE	IF	CITATIONS
91	Beyond Grade: Molecular Pathology of Malignant Gliomas. <i>Seminars in Radiation Oncology</i> , 2009, 19, 142-149.	2.2	31
92	Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. <i>Journal of Translational Medicine</i> , 2016, 14, 46.	4.4	31
93	Validation of Recursive Partitioning Analysis and Diagnosis-Specific Graded Prognostic Assessment in patients treated initially with radiosurgery alone. <i>Journal of Neurosurgery</i> , 2012, 117, 38-44.	1.6	31
94	Genetic Modulation of Neurocognitive Function in Glioma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3340-3346.	7.0	29
95	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. <i>Scientific Reports</i> , 2019, 9, 16830.	3.3	29
96	A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients. <i>Journal of Neurosurgical Anesthesiology</i> , 2017, 29, 46-58.	1.2	28
97	ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. <i>PLoS ONE</i> , 2018, 13, e0202860.	2.5	28
98	Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade. <i>Glia</i> , 2020, 68, 2148-2166.	4.9	28
99	Management of Brain Metastasis: Past Lessons, Modern Management, and Future Considerations. <i>Current Oncology Reports</i> , 2012, 14, 70-78.	4.0	27
100	Integrated Chromosome 19 Transcriptomic and Proteomic Data Sets Derived from Glioma Cancer Stem-Cell Lines. <i>Journal of Proteome Research</i> , 2014, 13, 191-199.	3.7	27
101	Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 2271-2276.	1.6	27
102	Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein-tyrosine kinase gene of the EPH family. <i>Human Molecular Genetics</i> , 1995, 4, 2033-2045.	2.9	26
103	<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 1395-1407.	7.0	26
104	A gene expression signature predicts recurrence-free survival in meningioma. <i>Oncotarget</i> , 2018, 9, 16087-16098.	1.8	26
105	Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. <i>Medical and Pediatric Oncology</i> , 2000, 35, 512-515.	1.0	25
106	Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting. <i>Oncotarget</i> , 2015, 6, 31007-31017.	1.8	24
107	Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 117, 308-314.	0.6	23
108	Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 179-188.	1.7	23

#	ARTICLE	IF	CITATIONS
109	ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM). <i>Neuro-Oncology</i> , 2019, 21, vi17-vi17.	1.2	23
110	Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. <i>Cancers</i> , 2019, 11, 2031.	3.7	23
111	Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. <i>Cancer Discovery</i> , 2021, 11, 2904-2923.	9.4	23
112	Brain Tumor Stem Cells. <i>Current Problems in Cancer</i> , 2008, 32, 124-142.	2.0	22
113	Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. <i>Gynecologic Oncology</i> , 2013, 131, 645-649.	1.4	22
114	Systematic Identification of Single Amino Acid Variants in Glioma Stem-Cell-Derived Chromosome 19 Proteins. <i>Journal of Proteome Research</i> , 2015, 14, 778-786.	3.7	22
115	Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma. <i>Journal of Neurosurgery</i> , 2018, 129, 1446-1455.	1.6	22
116	Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor-Initiating Cells. <i>Cancer Research</i> , 2013, 73, 3062-3074.	0.9	21
117	The Use of Global Profiling in Biomarker Development for Gliomas. <i>Brain Pathology</i> , 2011, 21, 88-95.	4.1	19
118	Cloning, Chromosomal Localization, Physical Mapping, and Genomic Characterization of HKR3. <i>Genomics</i> , 1996, 35, 289-298.	2.9	18
119	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. <i>Journal of Oncology Practice</i> , 2017, 13, 123-127.	2.5	18
120	The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells. <i>Oncotarget</i> , 2018, 9, 10497-10509.	1.8	18
121	Use of ENCODE Resources to Characterize Novel Proteoforms and Missing Proteins in the Human Proteome. <i>Journal of Proteome Research</i> , 2015, 14, 603-608.	3.7	17
122	Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. <i>Journal of Neuro-Oncology</i> , 2018, 137, 67-75.	2.9	17
123	Identification of Histological Correlates of Overall Survival in Lower Grade Gliomas Using a Bag-of-words Paradigm: A Preliminary Analysis Based on Hematoxylin & Eosin Stained Slides from the Lower Grade Glioma Cohort of The Cancer Genome Atlas. <i>Journal of Pathology Informatics</i> , 2017, 8, 9.	1.7	17
124	Prognostic and Predictive Markers in Glioma and Other Neuroepithelial Tumors. <i>Current Problems in Cancer</i> , 2008, 32, 97-123.	2.0	16
125	Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium. <i>Journal of Proteome Research</i> , 2013, 12, 135-150.	3.7	16
126	Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. <i>Oncotarget</i> , 2017, 8, 21741-21753.	1.8	16

#	ARTICLE	IF	CITATIONS
127	APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death. <i>Oncotarget</i> , 2017, 8, 54285-54296.	1.8	15
128	139â€ŒClinically Applicable and Biologically Validated MRI Radiomic Test Method Predicts Glioblastoma Genomic Landscape and Survival. <i>Neurosurgery</i> , 2016, 63, 156-157.	1.1	14
129	Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells. <i>Cancers</i> , 2021, 13, 5284.	3.7	14
130	A Comprehensive View of Human Chromosome 1. <i>Genome Research</i> , 1999, 9, 978-988.	5.5	13
131	A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. <i>Oncotarget</i> , 2017, 8, 90488-90495.	1.8	13
132	Large Scale Identification of Variant Proteins in Glioma Stem Cells. <i>ACS Chemical Neuroscience</i> , 2018, 9, 73-79.	3.5	12
133	Highâ€ŒThroughput Automated Singleâ€ŒCell Imaging Analysis Reveals Dynamics of Glioblastoma Stem Cell Population During State Transition. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 290-301.	1.5	12
134	ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features. , 2019, 38, 59-73.		12
135	Molecular biology of brain tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 23-34.	1.8	11
136	The proteomic landscape of glioma stem-like cells. <i>EuPA Open Proteomics</i> , 2015, 8, 85-93.	2.5	11
137	TMIC-14. TUMOR EVOLUTION OF GLIOMA INTRINSIC GENE EXPRESSION SUBTYPE ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2016, 18, vi202-vi202.	1.2	11
138	Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 46-52.	1.7	9
139	Spatial Distance Correlates With Genetic Distance in Diffuse Glioma. <i>Frontiers in Oncology</i> , 2019, 9, 676.	2.8	8
140	Identification of patient-derived glioblastoma stem cell (GSC) lines with the alternative lengthening of telomeres phenotype. <i>Acta Neuropathologica Communications</i> , 2019, 7, 76.	5.2	8
141	BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor. <i>Modern Pathology</i> , 2019, 32, 338-345.	5.5	8
142	Multigene Sets for Clinical Application in Glioma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 449-457.	4.9	6
143	Correlative study of epigenetic regulation of tumor microenvironment in spindle cell melanomas and cutaneous malignant peripheral nerve sheath tumors. <i>Scientific Reports</i> , 2020, 10, 12996.	3.3	6
144	World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology. <i>Frontiers in Oncology</i> , 2021, 11, 659800.	2.8	6

#	ARTICLE	IF	CITATIONS
145	Tumor Profiling: Development of Prognostic and Predictive Factors to Guide Brain Tumor Treatment. <i>Current Oncology Reports</i> , 2011, 13, 26-36.	4.0	5
146	Full automation of spinal stereotactic radiosurgery and stereotactic body radiation therapy treatment planning using Varian Eclipse scripting. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 122-131.	1.9	5
147	Stereotactic Radiation for Treating Primary and Metastatic Neoplasms of the Spinal Cord. <i>Frontiers in Oncology</i> , 2020, 10, 907.	2.8	5
148	Update on Radiation Therapy for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 77-93.	2.2	5
149	Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?. <i>Journal of Neuro-Oncology</i> , 2022, 158, 471-480.	2.9	5
150	Bagged gene shaving for the robust clustering of high-throughput data. <i>International Journal of Bioinformatics Research and Applications</i> , 2010, 6, 326.	0.2	4
151	Abstract 3348: UniD: unified and integrated diagnostic pipeline for malignant gliomas based on DNA methylation data. , 2017, , .		4
152	Stereotactic radiosurgery for glioblastoma considering tumor genetic profiles: an international multicenter study. <i>Journal of Neurosurgery</i> , 2022, 137, 42-50.	1.6	4
153	Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study. <i>Journal of Neuro-Oncology</i> , 2021, 155, 343-351.	2.9	4
154	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. <i>Neuro-Oncology</i> , 2022, 24, 331-357.	1.2	4
155	ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2019, 21, vi9-vi10.	1.2	3
156	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab035.	0.7	3
157	Hippocampal sparing in patients receiving radiosurgery for ≥25 brain metastases. <i>Radiotherapy and Oncology</i> , 2021, 161, 65-71.	0.6	3
158	Breaking Tradition to Bridge Bench and Bedside: Accelerating the MD-PhD-Residency Pathway. <i>Academic Medicine</i> , 2021, 96, 518-521.	1.6	2
159	Transcription Profiling of Brain Tumors: Tumor Biology and Treatment Stratification. , 2009, , 529-551.		2
160	Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. <i>Journal of Clinical Investigation</i> , 2014, 124, 4134-4134.	8.2	2
161	Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. <i>Journal of Neuro-Oncology</i> , 2022, 156, 185-193.	2.9	2
162	Tumor Prognostic Factors and the Challenge of Developing Predictive Factors. <i>Current Oncology Reports</i> , 2013, 15, 33-46.	4.0	1

#	ARTICLE	IF	CITATIONS
163	ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi20-vi21.	1.2	1
164	ACTR-24. A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi18-vi18.	1.2	1
165	Phase II Trial of Proton Therapy vs. Photon IMRT for GBM: Secondary Analysis Comparison of Progression Free Survival between RANO vs. Clinical Assessment. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab073.	0.7	1
166	Insight into the publicâ€™s interest in tumour treating fields. <i>British Journal of Cancer</i> , 2021, 125, 901-903.	6.4	1
167	Abstract 3944: Caveolin-mediated Tie2 nuclear translocation results in enhanced NHEJ repair and glioma radioresistance. , 2014, , .		1
168	Polymorphisms risk modeling for vascular toxicity in patients with glioblastoma treated on NRG Oncology/RTOG 0825.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2049-2049.	1.6	1
169	Risk of Second Primary Neoplasms of the Central Nervous System. <i>Advances in Radiation Oncology</i> , 2022, 7, 100969.	1.2	1
170	EPIG-05RADIORESISTANCE OF PODOPLANIN-EXPRESSING GLIOMA STEM CELLS IS ASSOCIATED WITH EZH2-DRIVEN POLYCOMB REPRESSIVE COMPLEX ACTIVITY. <i>Neuro-Oncology</i> , 2015, 17, v87.1-v87.	1.2	0
171	MTR-19A MACROPHAGE-/MICROGLIAL-RICH TUMOR MICROENVIRONMENT MIMICS PRONEURAL TO MESENCHYMAL TRANSITION IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v128.3-v128.	1.2	0
172	GENO-36GLIOMA SPHERE-FORMING CELLS REVEAL INTRINSIC GLOBAL HYPERMETHYLATION ASSOCIATED WITH GBM RADIATION RESISTANCE. <i>Neuro-Oncology</i> , 2015, 17, v99.5-v100.	1.2	0
173	DRES-04. DEVELOPMENT OF Aâ€šCRISPR-CAS9D10A TARGETABLE, HIGH-COMPLEXITY, SINGLE-CELL BARCODING APPROACH FOR ISOLATION OF TREATMENT RESISTANT SUBCLONES FROM HETEROGENOUS MALIGNANT GLIOMAS. <i>Neuro-Oncology</i> , 2017, 19, vi64-vi64.	1.2	0
174	GENE-36. ACCURATE DETECTION OF TERT PROMOTER MUTATION IN GLIOMAS USING INFINIUM DNA METHYLATION ARRAYS IDENTIFIES NOVEL EPIGENETIC ASSOCIATION. <i>Neuro-Oncology</i> , 2017, 19, vi100-vi100.	1.2	0
175	MLTI-01. IMMUNOLOGICAL REPROGRAMMING IN THE CNS TUMOR MICROENVIRONMENT AND THERAPEUTIC EFFICACY OF RADIOTHERAPY WITH STAT3 BLOCKADE. <i>Neuro-Oncology Advances</i> , 2019, 1, i14-i14.	0.7	0
176	RADI-27. ROLE OF STEREOTACTIC RADIOSURGERY IN THE CARE OF PATIENTS WITH >= 25 CUMULATIVE BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2019, 1, i27-i27.	0.7	0
177	BSCI-12. COMPREHENSIVE GENOMIC ANALYSIS OF BRAIN METASTASES FROM MULTIPLE CANCER TYPES. <i>Neuro-Oncology Advances</i> , 2019, 1, i3-i3.	0.7	0
178	NIMG-03. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR GBM: SECONDARY ANALYSIS COMPARISON OF PROGRESSION FREE SURVIVAL BETWEEN RANO VS. CLINICAL AND RADIOLOGICAL ASSESSMENT. <i>Neuro-Oncology</i> , 2019, 21, vi161-vi162.	1.2	0
179	RTHP-18. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR NEWLY DIAGNOSED GBM: SECONDARY ANALYSIS COMPARISON OF GENDER AND NEUTROPHIL-LYMPHOCYTE RATIO (NLR) IN GBM OUTCOMES. <i>Neuro-Oncology</i> , 2019, 21, vi213-vi213.	1.2	0
180	RTHP-23. PROSPECTIVE TRIAL OF CONVENTIONALLY FRACTIONATED DOSE CONSTRAINTS FOR RE-IRRADIATION OF PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019, 21, vi214-vi214.	1.2	0

#	ARTICLE	IF	CITATIONS
181	DDIS-32. MEK INHIBITORS INDUCES NEURONAL DIFFERENTIATION IN EGFR AMPLIFIED GLIOMA STEM LIKE CELLS. <i>Neuro-Oncology</i> , 2019, 21, vi70-vi70.	1.2	0
182	Abstract PO-019: Radiotherapy in cancer is associated with a deletion signature that contributes to poor patient outcomes. , 2021, , .		0
183	Abstract 2467: Podoplanin expressing cancer stem cells show increased resistance to DNA damage induced by ionizing radiation. , 2011, , .		0
184	Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.. , 2013, , .		0
185	Abstract 532: Circulating myeloid precursor profile as potential marker to differentiate radiation changes from tumor recurrence after brain stereotactic radiosurgery. , 2015, , .		0
186	Abstract 3483: Synergistic combination therapy with molecular targeted drugs in glioma stem-like cells. , 2015, , .		0
187	Abstract 3298: ABL1 is required for Tie2-mediated DNA repair in brain tumor stem cells. , 2015, , .		0
188	Abstract 4795: A novel gene fusion in glioblastoma and a radiation response methylation signature identified by genomic characterization of glioma sphere-forming cells. , 2015, , .		0
189	Abstract 695: Synergistic antitumor effects of polo like kinase inhibitor volasertib in combination with ionizing radiation in glioblastoma. , 2015, , .		0
190	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology/RTOG 0525 and 0825.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2007-2007.	1.6	0
191	Abstract 1646: A glioblastoma methylation assay (GaMA) developed from genomic analysis of glioma spheroid cultures predicts response to radiation therapy in patients with glioblastoma. , 2016, , .		0
192	Abstract 4217: First pre-clinical validation of radiogenomics in glioblastoma. , 2016, , .		0
193	Abstract 1505: Radiogenomics defines key genomic network driving GBM invasion. , 2016, , .		0
194	Comprehensive molecular and immune profiling of non-small cell lung cancer and matched distant metastases to suggest distinct molecular mechanisms underlying metastasis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8541-8541.	1.6	0
195	Relative thrombocytosis following chemoradiation of patients with glioblastoma to predict survival.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13527-e13527.	1.6	0
196	EPCO-11. IN VIVO FUNCTIONAL GENOMIC SCREEN IDENTIFIES WISP1 AS AN OVEREXPRESSED DRIVER OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii71-ii71.	1.2	0
197	Evaluation of <i>in vitro</i> and <i>in vivo</i> efficacy of pharmacological lysine-specific demethylase 1 (LSD1) inhibitors in glioblastoma stem cell (GSC) models. <i>FASEB Journal</i> , 2022, 36, .	0.5	0